Core Insights - The company achieved a milestone in 2025 by recording a net profit of $287 million, successfully turning around from a net loss of $645 million in the previous year, marking its first annual profit since inception [1] - Total revenue for the year reached $5.343 billion, representing a year-on-year growth of 40.2%, with product revenue netting $5.282 billion, up 39.8% [1] Revenue Breakdown - The core product, Baiyueze, generated $3.928 billion in global sales, a 48.6% increase, maintaining its leading position among BTK inhibitors [3] - Bai Ze An (Tislelizumab) contributed $737 million, growing by 18.8% [3] - Other products included Anjiao Wei (Denosumab) at $306 million, up 36.4%, and Beili Tuo (Bonetuzumab) at $104 million, up 40.2% [3] - Other income reached $60.97 million, a significant increase of 98.6%, primarily from royalties related to the collaboration with Amgen [4] Profitability and Cash Flow - Gross profit for 2025 was $4.67 billion, with a gross margin of 87.3%, up from 84.3% in 2024, driven by improved product mix and manufacturing efficiencies [5] - The company reported a net cash flow from operating activities of $1.128 billion, a turnaround from a net outflow of $141 million in the previous year [1] Cost Structure and Efficiency - Research and development expenses totaled $2.146 billion, a 9.9% increase, while sales and administrative expenses were $2.081 billion, up 13.7% [6] - The combined expenses accounted for 78.6% of product revenue, down from 90.2% the previous year, indicating improved operational leverage [6] Financial Health - As of the end of 2025, total assets were $8.189 billion, with shareholder equity at $4.361 billion and total liabilities at $3.827 billion [8] - The company secured approximately $768 million in term loans from financial institutions for refinancing short-term operational funding [8] Pipeline Progress - The company is advancing its pipeline with the approval of Sotokura (a new generation BCL2 inhibitor) expected in January 2026 for treating relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukemia [9] - The HERIZON-GEA-01 study for Bai He An (Zanidatamab) achieved positive endpoints, paving the way for a market application in HER2-positive gastric adenocarcinoma [9] - The company is uniquely positioned with potential best-in-class candidates across three key targets in chronic lymphocytic leukemia [9]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 截至2025年12月31日止年度 全年業績公告 百濟神州有限公司連同其子公司（「本公司」或「百濟神州」或「我們」）謹此公佈本 公司截至2025年12月31日止年度（「報告期」）的綜合業績連同2024年相應期間的 比較數字，其乃根據美國公認會計原則（「美國公認會計原則」或「GAAP」）編製並 由本公司董事會（「董事會」）審計委員會（「審計委員會」）審閱。 財務摘要 1 | | | 截至12月31日止年度 | | | --- | --- | --- | --- | | | 附註 | 2025 | 2024 | | | | 千美元 | 千美元 | | 收入 | | | | | 產品收入，淨額 | 15 | 5,282,061 | 3,779,546 | | 其他收入 | 3 | 60,972 | ...

Core Viewpoint - BeiGene (06160.HK) reported a significant revenue increase for the fiscal year ending December 31, 2025, with total revenue rising by approximately $1.5 billion or about 40.2% to around $5.3 billion [1] Financial Performance - Total revenue for the fiscal year ending December 31, 2025, increased by approximately $1.5 billion or about 40.2% to around $5.3 billion compared to the fiscal year ending December 31, 2024 [1] - Product revenue also saw a rise of approximately $1.5 billion or about 39.8% to around $5.3 billion for the same period [1] - The net profit for the fiscal year ending December 31, 2025, was approximately $287 million, a significant turnaround from a net loss of approximately $645 million for the fiscal year ending December 31, 2024 [1] - Basic and diluted earnings per share for the fiscal year ending December 31, 2025, were $0.20 [1] Product Performance - The product "Tislelizumab" (百悦泽®) maintains its leading position in global revenue among BTK inhibitors [1] - "Zanubrutinib" (百泽安®) continues to receive new indication approvals and broader reimbursement coverage across multiple markets [1] - The commercialization of hematologic oncology products is gradually progressing, while the solid tumor product portfolio is consistently delivering encouraging data [1]

Core Viewpoint - BeiGene is projected to achieve a revenue of $5.343 billion in 2025, representing a year-on-year growth of 40.2%. The company is also expected to report a net profit of $287 million, a significant turnaround from a net loss of $645 million in the same period last year [1]. Financial Performance - Revenue for 2025 is estimated at $5.343 billion, indicating a growth rate of 40.2% compared to the previous year [1]. - The net profit is forecasted to be $287 million, contrasting with a net loss of $645 million in the same quarter of the previous year [1].

Core Insights - The company BeiGene is projected to achieve a revenue of $5.343 billion in 2025, representing a year-on-year growth of 40.2% [1] - The net profit is expected to reach $287 million, a significant turnaround from a net loss of $645 million in the same period last year [1] Financial Performance - Revenue forecast for 2025: $5.343 billion, up 40.2% year-on-year [1] - Expected net profit: $287 million, compared to a net loss of $645 million in the previous year [1]

Core Insights - The company BeiGene announced projected revenue of $5.343 billion for 2025, representing a year-over-year growth of 40.2% [1] - The company expects a net profit of $287 million, a significant turnaround from a net loss of $645 million in the same period last year [1] Financial Performance - Projected revenue for 2025 is $5.343 billion, indicating a robust growth trajectory [1] - The anticipated net profit of $287 million marks a substantial improvement compared to the previous year's net loss of $645 million [1]

Financial Performance - Total revenue for the year ended December 31, 2025, increased by approximately $1.5 billion or about 40.2% to approximately $5.3 billion compared to the year ended December 31, 2024[3]. - Product revenue for the year ended December 31, 2025, rose by approximately $1.5 billion or about 39.8% to approximately $5.3 billion compared to the previous year[3]. - Net profit for the year ended December 31, 2025, was approximately $286.9 million, a significant improvement from a net loss of approximately $644.8 million for the year ended December 31, 2024[3]. - Basic and diluted earnings per share for the year ended December 31, 2025, were $0.20 and $0.19, respectively, compared to losses of $0.47 per share for the previous year[3]. - The company reported a comprehensive income of approximately $357.7 million for the year ended December 31, 2025, compared to a comprehensive loss of approximately $694.3 million for the previous year[5]. - The company reported a net loss of $644,786,000 for the year ending December 31, 2024, which improved to a net profit of $286,933,000 for the year ending December 31, 2025[132]. Cash and Liquidity - Cash and cash equivalents as of December 31, 2025, were approximately $4.5 billion, up from approximately $2.6 billion as of December 31, 2024[6]. - Operating cash flow generated was $1,127,580 thousand, compared to an outflow of $140,631 thousand in the previous year[8]. - Cash and cash equivalents increased to $4,547,530 thousand by the end of 2025, up from $2,627,410 thousand at the end of 2024[9]. - The company raised $911,000 thousand from future royalty sales, contributing to a net cash inflow from financing activities of $1,059,451 thousand[9]. - Cash and cash equivalents increased significantly from $2,638.7 million in 2024 to $4,609.6 million in 2025, with operating cash flow generating $1.1 billion, a $1.3 billion increase year-over-year[180]. Assets and Liabilities - Total assets as of December 31, 2025, amounted to approximately $8.2 billion, compared to approximately $5.9 billion as of December 31, 2024[6]. - Total liabilities as of December 31, 2025, increased to approximately $3.8 billion from approximately $2.6 billion as of December 31, 2024[7]. - Shareholders' equity as of December 31, 2025, was approximately $4.4 billion, an increase from approximately $3.3 billion as of December 31, 2024[7]. - The company reported total liabilities of $3,827,379,000 as of December 31, 2025, compared to $3,332,222,000 in 2024, indicating an increase of about 14.9%[124]. - The total equity as of December 31, 2025, was $4,361,194,000, up from $3,332,222,000 in 2024, reflecting a growth of approximately 30.9%[124]. Research and Development - Research and development expenses increased to $510,857 thousand in 2025, up from $441,618 thousand in 2024[8]. - Research and development costs for 2025 amounted to $2,145,868,000, an increase from $1,953,295,000 in 2024[89]. - The company has over 20 CDAC and degradation antibody conjugate projects in drug discovery and clinical development stages, indicating a robust pipeline for future growth[143]. - Adjusted R&D expenses rose to $1.86 billion in 2025, up 11.3% from $1.67 billion in 2024[166]. Collaborations and Partnerships - The company has entered into collaboration agreements for the research, development, and commercialization of drugs, including royalty income from the sale of IMDELLTRA® outside China[23]. - The company received a $650 million upfront payment from Novartis for the collaboration and licensing agreement related to the development and commercialization of Tislelizumab in North America, Europe, and Japan[32]. - The company received a $300 million upfront payment from Novartis for the collaboration and licensing agreement concerning the TIGIT inhibitor Osemitamab, which was also terminated in July 2023[34]. - The company and Amgen signed multiple amendments to their collaboration agreement, expanding commercialization rights and adjusting financial responsibilities for specific products[28]. Tax and Regulatory Matters - The company confirmed Switzerland as its tax residency and adopted ASU 2023-09 starting from the fiscal year ending December 31, 2025, with a global effective tax rate of 31.2%[58]. - The deferred tax assets as of December 31, 2025, totaled $3,692,017,000, with a valuation allowance of $3,648,017,000, resulting in a net deferred tax asset of $44,000[62]. - The company incurred accrued interest and penalties of $2,676,000 in the U.S. and $3,264,000 in China related to uncertain tax positions as of December 31, 2025[64]. Employee and Stock Options - The company approved the 2018 Employee Stock Purchase Plan, reserving 3,500,000 shares initially, which was later increased to 12,425,315 shares by June 2024[95]. - The fair value of vested employee stock options rewards was $55,954,000 and $68,420,000 for the years ended December 31, 2025, and 2024, respectively[101]. - The estimated unrecognized compensation cost related to unvested stock options was $63,875,000, expected to be recognized over a weighted average period of 2.4 years[100]. Future Outlook and Strategy - The company plans to continue expanding its product offerings and market presence, particularly in the U.S. and China, with several new product launches anticipated[83]. - The company is focusing on lifecycle management to maximize value for shareholders and patients in the hematological oncology space, leveraging its cornerstone product Baiyueze®[144]. - The company is actively seeking strategic partnerships to strengthen its business and create long-term value for shareholders[146].

BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊發的《百濟神州有限公司關於續聘2026年 度審計機構的公告》，僅供參閱。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2026年3月25日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事王 曉東博士，以及獨立非執行董事Olivier Brandicourt博士、Margaret Han Dugan 博士、Michael Goller先生、Anthony C. Hooper先生、Ranjeev Krishana先生、 Alessandro Riva博士、Corazon ( ...

A 股代码：688235 A 股简称：百济神州 公告编号：2026-004 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 关于续聘2026年度审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟聘任审计机构：安永华明会计师事务所（特殊普通合伙）为百济神州有 限公司（以下简称"公司"或"百济神州"）A 股财务报表和内部控制年度审 计机构；Ernst & Young（安永会计师事务所）为公司港股财务报表年度审计机 构；Ernst & Young LLP 为公司美股财务报表和内部控制年度审计机构；Ernst & Young AG 为公司瑞士法定审计机构。 一、续聘的审计机构的基本情况 （一）机构信息 1、安永华明会计师事务所（特殊普通合伙）（以下简称"安永华明"） （1）基本信息 安永华明于 1992 年 9 月成立，2012 年 8 月完成本土化转制，从一家中外合 作的有限责任制事务所转制为特殊普通合伙制事务所。安永华明总部设在北京， 注册地址为北京市东城区东长安街 ...

Group 1 - The core viewpoint of the article is the strategic collaboration between Lao Bai Xing Pharmacy and Innovent Biologics to commercialize the innovative drug Masitide (Xin Er Mei) for metabolic disease management [1] - The partnership aims to integrate Innovent's core capabilities in innovative research and development with Lao Bai Xing's extensive retail network and professional service system to accelerate the nationwide distribution of Masitide [1] - Masitide is an innovative drug developed by Innovent Biologics for weight loss and blood sugar reduction, and Lao Bai Xing has over ten thousand stores covering major cities and county markets across the country [1] Group 2 - Both companies have reached a consensus on specific cooperation details, including supply chain assurance, patient service system development, and market promotion strategies [1] - The collaboration will utilize a comprehensive model of "store counters + pharmacist training + patient community operations" to establish a benchmark in metabolic disease management [1] - Innovent's founder emphasized that Lao Bai Xing's channel capabilities and professional services are crucial for reaching patients with Masitide, while Lao Bai Xing's founder highlighted the alignment of Masitide's clinical advantages with their chronic disease service system [1]